PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Galderma
Sponsor:
Information provided by (Responsible Party):
Galderma
ClinicalTrials.gov Identifier:
NCT01766440
First received: January 9, 2013
Last updated: August 27, 2014
Last verified: August 2014
  Purpose

The purpose of this study is to determine if the calcitriol absorption in pediatric subjects is comparable to that in adults and adolescents, with no significant impact on calcium/phosphorus metabolism.


Condition Intervention Phase
Plaque Psoriasis
Drug: Calcitriol 3 mcg/g ointment
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis

Resource links provided by NLM:


Further study details as provided by Galderma:

Primary Outcome Measures:
  • C max of calcitriol plasma level [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • C min of calcitriol plasma level [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • T max of calcitriol plasma level [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
  • AUC of calcitriol plasma level [ Time Frame: Day 14 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Calcium homeostasis parameters [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
    Serum calcium, albumin-adjusted calcium, serum phosphorus, serum albumin, intact PTH and urinary calcium/creatinine ratio


Estimated Enrollment: 30
Study Start Date: March 2013
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Calcitriol 3 mcg/g ointment
Topical application every 12 hours for 14 consecutive days
Drug: Calcitriol 3 mcg/g ointment

  Eligibility

Ages Eligible for Study:   2 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female pediatric subjects, 2 to 12 years of age inclusive at screening
  • Clinical diagnosis of plaque type psoriasis involving 5% through 35% body surface area at screening and baseline (excluding face and scalp)

Exclusion Criteria:

  • Subjects with guttate or pustular psoriasis, erythrodermic psoriasis or active infection
  • Subjects with hypercalcemia and out of range urinary calcium/creatinine ratio at screening
  • Subjects with secondary hyperparathyroidism at screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01766440

Contacts
Contact: Sarah Anderson 609-860-8236 sarah.anderson@galderma.com

Locations
United States, California
Rady Children's Hospital - Pediatric and Adolescent Dermatology Recruiting
San Diego, California, United States, 92123
Contact: Nicola Borok, RN,CCRC    858-576-1700 ext 4295    nborok@rchsd.org   
Principal Investigator: Lawrence Eichenfield, MD         
United States, Florida
Ameriderm Research Withdrawn
Ormond Beach, Florida, United States
United States, Indiana
Dawes Fretzin Clinical Research Group, LLC Recruiting
Indianapolis, Indiana, United States, 46256
Contact: Ashley Wallace    317-621-7731 ext 119    awallace@ecommunity.com   
Principal Investigator: Scott A Fretzin, MD         
United States, Michigan
University of Michigan Medical Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Kathryn Keeley, CCRP    734-763-9187    ktkeeley@umich.edu   
Principal Investigator: Yolanda Helfrich, MD         
United States, North Carolina
University of North Carolina Dermatology and Skin Cancer Center Recruiting
Chapel Hill, North Carolina, United States, 27516
Contact: Erika Hanami    919-843-5126      
Principal Investigator: Aida Lugo-Somolinos, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Laurie Vanderah, RN, BSN    513-803-0003      
Principal Investigator: Kara Shah, MD         
United States, Tennessee
TriCities Skin and Cancer Withdrawn
Johnson City, Tennessee, United States, 37601
United States, Texas
Menter Dermatology Research Institute Recruiting
Dallas, Texas, United States, 75246
Contact: Mia Robinson    972-354-7992      
Principal Investigator: Alan Menter, MD         
Clinical Trials of Texas, Inc. Recruiting
San Antonio, Texas, United States
Contact: Amy Griffith    210-949-0122      
Principal Investigator: Elizabeth Tichy, MD         
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Janna Stults, MPH    206-884-3691    janna.stults@seattlechildrens.org   
Principal Investigator: Heather Brandling-Bennett, MD         
Sponsors and Collaborators
Galderma
  More Information

No publications provided

Responsible Party: Galderma
ClinicalTrials.gov Identifier: NCT01766440     History of Changes
Other Study ID Numbers: RD.06. SPR.18104
Study First Received: January 9, 2013
Last Updated: August 27, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Calcitriol
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on September 14, 2014